HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Actinomycin D for reinduction of remission in dogs with resistant lymphoma.

Abstract
Twenty-five dogs with malignant lymphoma refractory to chemotherapy were treated with actinomycin D at a median dose of 0.7 mg/m2 (range, 0.5 to 0.9 mg/m2) every 3 weeks. The dogs treated had received between 2 and 8 chemotherapeutic agents (median 7), for a median of 266 days before being treated with actinomycin D. For 23 of the 25 dogs, previous chemotherapy included doxorubicin. No dog responded to actinomycin D chemotherapy.
AuthorsA S Moore, G K Ogilvie, D M Vail
JournalJournal of veterinary internal medicine (J Vet Intern Med) 1994 Sep-Oct Vol. 8 Issue 5 Pg. 343-4 ISSN: 0891-6640 [Print] United States
PMID7837110 (Publication Type: Journal Article)
Chemical References
  • Dactinomycin
  • Doxorubicin
Topics
  • Animals
  • Dactinomycin (therapeutic use)
  • Dog Diseases (drug therapy)
  • Dogs
  • Doxorubicin (therapeutic use)
  • Female
  • Lymphoma (drug therapy, veterinary)
  • Male
  • Neoplasm Staging (veterinary)
  • Prognosis
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: